Monte Rosa Therapeutics, Inc. GLUE Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s common stock?
- Monte Rosa Therapeutics, Inc. (GLUE) reported common stock of $8K in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s common stock changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s common stock increased by 33.3% year-over-year, from $6K to $8K.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s common stock?
- Over 5 years (2020 to 2025), Monte Rosa Therapeutics, Inc.'s common stock has grown at a 47.6% compound annual growth rate (CAGR), from $1K to $7K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).